新型吲哚衍生物作为用于治疗精神病、精神疾病和中枢神经系统疾病的血清素能致幻剂。
Novel Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2025 May 30;16(6):982-983. doi: 10.1021/acsmedchemlett.5c00309. eCollection 2025 Jun 12.
Abstract
Provided herein are novel indole derivatives as serotonergic psychedelic agents, pharmaceutical compositions, use of such compounds in treating psychosis, mental illness and central nervous system (CNS) disorders, and processes for preparing such compounds.
摘要
本文提供了作为血清素能致幻剂的新型吲哚衍生物、药物组合物、此类化合物在治疗精神病、精神疾病和中枢神经系统（CNS）疾病中的用途，以及制备此类化合物的方法。
相似文献
1
Novel Indole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.新型吲哚衍生物作为用于治疗精神病、精神疾病和中枢神经系统疾病的血清素能致幻剂。
ACS Med Chem Lett. 2025 May 30;16(6):982-983. doi: 10.1021/acsmedchemlett.5c00309. eCollection 2025 Jun 12.
2
Novel Indoline Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness and CNS Disorders.新型吲哚啉衍生物作为用于治疗精神病、精神疾病和中枢神经系统疾病的血清素能致幻剂。
ACS Med Chem Lett. 2025 Jan 23;16(2):196-197. doi: 10.1021/acsmedchemlett.5c00004. eCollection 2025 Feb 13.
3
Novel 3-Cycloaminoindole Compounds as Serotonergic Psychedelic Agents for Treating Psychosis, Mental Illness, and CNS Disorders.新型3-环氨基吲哚化合物作为用于治疗精神病、精神疾病和中枢神经系统疾病的5-羟色胺能致幻剂。
ACS Med Chem Lett. 2025 Jan 4;16(2):190-191. doi: 10.1021/acsmedchemlett.4c00615. eCollection 2025 Feb 13.
4
Novel 3-Pyrrolidineindole Derivatives as Serotonergic Psychedelic Agents for Treating Psychosis and Mental Illnesses Such as Depression and Post-Traumatic Stress Disorder.新型3-吡咯烷吲哚衍生物作为5-羟色胺能致幻剂用于治疗精神病以及抑郁症和创伤后应激障碍等精神疾病。
ACS Med Chem Lett. 2024 Dec 10;16(1):18-19. doi: 10.1021/acsmedchemlett.4c00581. eCollection 2025 Jan 9.
5
Novel Azaindazole Derivatives as HCN2 Modulators for Treating Central Nervous System and Psychiatric Disorders, Namely, Schizophrenia, Autism, and Mood Disorders.新型氮杂吲哚衍生物作为HCN2调节剂用于治疗中枢神经系统和精神疾病，即精神分裂症、自闭症和情绪障碍。
ACS Med Chem Lett. 2025 May 9;16(6):927-928. doi: 10.1021/acsmedchemlett.5c00228. eCollection 2025 Jun 12.
6
Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.作为用于治疗精神疾病或中枢神经系统疾病的5-HT2A激动剂的新型化合物。
ACS Med Chem Lett. 2025 Feb 11;16(3):377-378. doi: 10.1021/acsmedchemlett.5c00066. eCollection 2025 Mar 13.
7
Novel Indole and Pyrrolopyridine Derivatives as GPR17 Modulators for Treating Multiple Sclerosis.作为用于治疗多发性硬化症的GPR17调节剂的新型吲哚和吡咯并吡啶衍生物
ACS Med Chem Lett. 2025 Apr 9;16(5):736-737. doi: 10.1021/acsmedchemlett.5c00176. eCollection 2025 May 8.
8
Novel Imidazotriazine Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Disorders.新型咪唑并三嗪衍生物作为治疗炎症和自身免疫性疾病的白细胞介素-17调节剂
ACS Med Chem Lett. 2024 Dec 10;16(1):12-13. doi: 10.1021/acsmedchemlett.4c00573. eCollection 2025 Jan 9.
9
Novel Ergoline Compounds as 5-HT2A Agonists for Treating Mood Disorders Such as Depressive Disorders and Bipolar Disorders.新型麦角灵化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2024 Dec 20;16(1):32-33. doi: 10.1021/acsmedchemlett.4c00593. eCollection 2025 Jan 9.
10
Novel Tryptamine Compounds as 5-HT2A Agonists for Treating Mood Disorders such as Depressive Disorders and Bipolar Disorders.新型色胺化合物作为5-HT2A激动剂用于治疗情绪障碍，如抑郁症和双相情感障碍。
ACS Med Chem Lett. 2025 Feb 13;16(3):373-374. doi: 10.1021/acsmedchemlett.5c00047. eCollection 2025 Mar 13.
本文引用的文献
1
5-HT receptors: Pharmacology and functional selectivity.5-羟色胺受体：药理学与功能选择性
Pharmacol Rev. 2025 Jul;77(4):100059. doi: 10.1016/j.pharmr.2025.100059. Epub 2025 Apr 23.
2
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity.N，N-二甲基色胺的演变：从代谢途径到脑连接性
Psychopharmacology (Berl). 2025 Apr 11. doi: 10.1007/s00213-025-06777-z.
3
Novel Compounds as 5-HT2A Agonists for Treating Mental Illness or CNS Disorders.作为用于治疗精神疾病或中枢神经系统疾病的5-HT2A激动剂的新型化合物。
ACS Med Chem Lett. 2025 Feb 11;16(3):377-378. doi: 10.1021/acsmedchemlett.5c00066. eCollection 2025 Mar 13.
4
Psychedelic-Induced Neural Plasticity: A Comprehensive Review and a Discussion of Clinical Implications.致幻剂诱导的神经可塑性：全面综述及临床意义探讨
Brain Sci. 2025 Jan 25;15(2):117. doi: 10.3390/brainsci15020117.
5
Exploring DMT: Endogenous role and therapeutic potential.探索二甲基色胺：内源性作用及治疗潜力。
Neuropharmacology. 2025 May 1;268:110314. doi: 10.1016/j.neuropharm.2025.110314. Epub 2025 Jan 18.
6
Antidepressant and anxiolytic effects of activating 5HT2A receptors in the anterior cingulate cortex and the theoretical mechanisms underlying them - A scoping review of available literature.前扣带回皮层中5HT2A受体激活的抗抑郁和抗焦虑作用及其潜在理论机制——现有文献的综述
Brain Res. 2025 Jan 1;1846:149226. doi: 10.1016/j.brainres.2024.149226. Epub 2024 Sep 7.
Zotero 插件